Stock Rating Downgrade
Reflecting eroding fundamentals and low Appreciation Potential, the Value Trend Rating for OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) weakened in the last week. VRSK’s current Value Trend Rating is D and the prior Rating was C. Details supporting this lower rating are included in our next report.
Recent Price Action
OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) stock declined slightly by -0.6% on 4/8/24. The stock closed at $226.38. Trading volume in this decline was normal. The stock has performed in line with the market over the last nine months and has declined -4.0% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, VRSK is expected to continue to be a major Value Builder.
VERISK ANALYTICS INC has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. VERISK ANALYTICS INC has a neutral Power Rating of 43 and a slightly negative Appreciation Score of 38, and the Negative Value Trend Rating results.
Be the first to comment